BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
4.82M
Enterprise Value 3
2.69M
Trailing P/E
N/A
Forward P/E 1
-0.32
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
321.19
Price/Book (mrq)
2.18
Enterprise Value/Revenue 3
179.19
Enterprise Value/EBITDA 6
-0.20

Trading Information

Stock Price History

Beta (3Y Monthly) 0.10
52-Week Change 3 -92.46%
S&P500 52-Week Change 3 8.78%
52 Week High 3 4.8000
52 Week Low 3 0.3000
50-Day Moving Average 3 0.3546
200-Day Moving Average 3 0.7848

Share Statistics

Avg Vol (3 month) 3 348.25k
Avg Vol (10 day) 3 362.46k
Shares Outstanding 5 10.68M
Float 13.26M
% Held by Insiders 1 1.64%
% Held by Institutions 1 18.95%
Shares Short (Sep 30, 2019) 4 75.49k
Short Ratio (Sep 30, 2019) 4 0.19
Short % of Float (Sep 30, 2019) 4 0.77%
Short % of Shares Outstanding (Sep 30, 2019) 4 0.53%
Shares Short (prior month Aug 30, 2019) 4 239.55k

Dividends & Splits

Forward Annual Dividend Rate 4 N/A
Forward Annual Dividend Yield 4 N/A
Trailing Annual Dividend Rate 3 N/A
Trailing Annual Dividend Yield 3 N/A
5 Year Average Dividend Yield 4 N/A
Payout Ratio 4 0.00%
Dividend Date 3 N/A
Ex-Dividend Date 4 N/A
Last Split Factor (new per old) 2 25/1
Last Split Date 3 Apr 26, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Jan 31, 2019
Most Recent Quarter (mrq) Jul 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm) -91,623.33%

Management Effectiveness

Return on Assets (ttm) -136.39%
Return on Equity (ttm) -454.52%

Income Statement

Revenue (ttm) 15k
Revenue Per Share (ttm) 0.00
Quarterly Revenue Growth (yoy) N/A
Gross Profit (ttm) -26k
EBITDA -13.68M
Net Income Avi to Common (ttm) -14.71M
Diluted EPS (ttm) -1.5580
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 3.29M
Total Cash Per Share (mrq) 0.23
Total Debt (mrq) 1.24M
Total Debt/Equity (mrq) 56.15
Current Ratio (mrq) 1.87
Book Value Per Share (mrq) 0.16

Cash Flow Statement

Operating Cash Flow (ttm) -13.6M
Levered Free Cash Flow (ttm) -8.35M